EVP-0015962
EVP-0015962 is an orally active, blood-brain barrier-permeable γ-secretase inhibitor with an IC50 of 3.9 μM. EVP-0015962 alters γ-secretase-mediated cleavage of amyloid precursor protein, reduces Aβ42 production and increases Aβ38 production. EVP-0015962 reduces Aβ aggregates, amyloid plaques and inflammatory markers in the brains of mice, and improves their cognitive impairment. EVP-0015962 can be used for the research of Alzheimer's disease.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1447811-26-8
- Formule: C22H19ClF6O3
- Masse moléculaire:480.83
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| H4 | IC50 |
67 nM
Compound: EVP-0015962
|
Modulation of gamma-secretase in human H4 cells expressing wild type APP751 assessed as inhibition of intracellular amyloid beta 42 production after 16 to 18 hrs by sandwich ELISA
Modulation of gamma-secretase in human H4 cells expressing wild type APP751 assessed as inhibition of intracellular amyloid beta 42 production after 16 to 18 hrs by sandwich ELISA
|
[PMID: 26142947] |
EVP-0015962 (0.003-10 μM; 16-18 h) acts as a γ-secretase modulator in H4-APP751 cells, potently decreasing Aβ42 (IC50 = 67 nM) and increasing Aβ38 without altering total Aβ levels at non-cytotoxic concentrations[1].
EVP-0015962 (0.01-30 μM; 24 h) modulates γ-secretase in rat primary neocortical cultures, decreasing Aβ42 (IC50 = 427 nM) and increasing Aβ38 without reducing Aβ1-ₓ levels or inducing cytotoxicity at active concentrations[1].
EVP-0015962 (0.001-100 μM; 3 h) modulates γ-secretase in a cell-free reconstituted system, selectively lowering Aβ42 (IC50 = 3.9 μM) without inhibiting AICD production or altering Aβ40 levels[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
EVP-0015962 (20-60 mg/kg/day; p.o.; continuous via food formulation; 50 weeks) is well-tolerated in male Tg2576 mice, reduces brain Aβ42 levels by 53-89%, aggregated Aβ by 73% at the high dose, amyloid plaque burden, and reactive gliosis, with a dose-dependent trend in efficacy[1].
EVP-0015962 (20-60 mg/kg/day; p.o.; continuous via food formulation; 11 weeks) reverses the contextual fear conditioning cognitive deficit in 30-33-week-old male Tg2576 mice[1].
EVP-0015962 (30 mg/kg; p.o.; single dose) does not reverse the contextual fear conditioning cognitive deficit in 30-week-old male Tg2576 mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Tg2576 (B6;SJL-Tg(APPSWE)2576Kha) (male, 21 weeks old, 24-35 g)[1]
-
Dosage:10 mg/kg; 30 mg/kg
-
Administration:p.o.; single dose
-
Result:Reduced brain Aβ42 levels by 22% relative to vehicle controls (not statistically significant).
Reduced brain Aβ42 levels by 39% relative to vehicle controls.
Left AβTotal levels unchanged with both doses.
-
Animal Model:Tg2576 (B6;SJL-Tg(APPSWE)2576Kha) (male, 17-26 weeks old at study start)[1]
-
Dosage:20 mg/kg/day; 60 mg/kg/day
-
Administration:p.o.; continuous via food formulation; 50 weeks
-
Result:Achieved brain concentrations of 2.5 μM (20 mg/kg/day group) and 8.3 μM.
Reduced TBS-soluble Aβ42 by 53% in the 20 mg/kg/day group and 89% in the 60 mg/kg/day group relative to controls.
Reduced formic acid-extractable Aβ42 by 53% in the 20 mg/kg/day group and 86% in the 60 mg/kg group relative to controls.
Increased TBS-soluble Aβ38 by 78% in the 60 mg/kg/day group relative to controls; the 20 mg/kg/day group showed no significant increase.
Reduced formic acid-extractable AβTotal by 49% in the 20 mg/kg/day group and 64% in the 60 mg/kg/day group relative to controls.
-
Animal Model:Tg2576 (B6;SJL-Tg(APPSWE)2576Kha) (male, 19-22 weeks old at study start, tested at 30-33 weeks old)[1]
-
Dosage:20 mg/kg/day; 60 mg/kg/day
-
Administration:p.o.; continuous via food formulation; 11 weeks
-
Result:Reversed the cognitive deficit (reduced percent freezing) in Tg2576 mice completely, with percent freezing levels in both treatment groups not significantly different from wild-type controls and significantly higher than control diet Tg2576 mice.
-
Animal Model:Tg2576 (B6;SJL-Tg(APPSWE)2576Kha) (male, 30 weeks old)[1]
-
Dosage:30 mg/kg
-
Administration:p.o.; single dose
-
Result:Did not reverse the genotype-associated cognitive deficit (reduced percent freezing) in Tg2576 mice relative to wild-type mice; percent freezing levels in EVP-0015962-treated Tg2576 mice remained significantly lower than those in EVP-0015962-treated wild-type mice.
Chemical Information
-
CAS No. 1447811-26-8
-
Masse moléculaire 480.83
-
Formule C22H19ClF6O3
-
SMILES
O=C([C@@H](C1=CC(C2=CC=C(C=C2)C(F)(F)F)=C(C(Cl)=C1)OCC(F)(F)F)CC3CCC3)O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
EVP-0015962 Related Classifications
HY-117521 Related Classifications
Powered by Bioz